- The incretin class, semaglutide and tirzepatide especially, enrolled large numbers of women in its clinical trials, making it the best-studied group on this site in female subjects even though outcomes were rarely stratified by menopausal status.
- Tirzepatide's label warns that it may reduce the effectiveness of oral hormonal contraceptives, a genuinely important and frequently omitted fact for women that a semaglutide-versus-tirzepatide comparison should surface.
- Retatrutide and cagrilintide are investigational, not approved, so their female-specific and long-term safety records do not yet exist, and both are contraindicated in pregnancy.
If any group on this site earns the phrase "strong human data," it is the incretin compounds. Semaglutide and tirzepatide are approved medicines with large clinical programs that enrolled substantial numbers of women, and retatrutide and cagrilintide are investigational agents whose trials have also recruited women in meaningful numbers. That female enrollment is real and worth stating plainly. It also does not answer every question a woman might have, and one of the most practical, an interaction with oral contraceptives, is the kind of detail most peptide sources skip.
The mechanisms, briefly
Semaglutide is a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite via central pathways. Tirzepatide is a dual GIP and GLP-1 receptor agonist engaging both incretin pathways in one molecule. Retatrutide is an investigational triple agonist that adds the glucagon receptor to those two, pairing appetite and glucose signaling with glucagon-driven energy expenditure. Cagrilintide is a long-acting amylin analog studied for satiety and slowed gastric emptying, often paired with semaglutide in a combination known as CagriSema. Each has been studied for these mechanisms; none is described here as a demonstrated weight result.
| Compound | Class | Status | Female-trial note |
|---|---|---|---|
| Semaglutide | GLP-1 agonist | Approved (T2D, weight management) | Large female enrollment; outcomes not stratified by menopausal status |
| Tirzepatide | GIP/GLP-1 dual agonist | Approved (T2D, weight management) | Large female enrollment; documented oral-contraceptive interaction |
| Retatrutide | GIP/GLP-1/glucagon triple agonist | Investigational (Phase 2) | Phase 2 obesity trials enrolled women; no long-term female safety data |
| Cagrilintide | Amylin analog | Investigational | Trials enroll women; female-specific effects not separately established |
The tirzepatide label warns that it may reduce the effectiveness of ORAL hormonal contraceptives, likely through delayed gastric emptying. The label advises a non-oral contraceptive method, or a backup barrier method, for 4 weeks after starting and after each dose increase. Semaglutide's oral formulation also carries specific timing guidance relevant to oral-contraceptive users. For retatrutide and cagrilintide, a comparable interaction has not been characterized, though delayed gastric emptying makes an effect on oral-drug absorption plausible and unstudied. This is information to raise with a clinician, not a protocol.
What female enrollment does and does not settle
Large female enrollment is the reason this class stands out, but it has limits worth naming. For semaglutide, many studies included women, yet appetite and nausea effects have not been systematically evaluated across menstrual cycle phases, and there are no dedicated trials in perimenopausal weight change; the broad enrollment spans that age range without being stratified by menopausal status. Tirzepatide sits in the same position. So the class answers "were women studied" with a clear yes and answers "were female-specific and cycle-specific questions analyzed" with a much more tentative one.
Approved versus investigational is not a small distinction
Semaglutide and tirzepatide are approved and carry labels, which is why their pregnancy and contraceptive cautions can be stated as documented facts. Retatrutide and cagrilintide are investigational. Retatrutide remains in Phase 2 development, has no established dose outside trials, and has no pregnancy or lactation safety data, so there is no basis to consider it safe in those settings. Cagrilintide is likewise investigational, with once-weekly subcutaneous dosing used in trials and no separately established female-specific effects. Treating an investigational triple agonist as interchangeable with an approved medicine is a category error the evidence does not support.
Any dose or route mentioned here, titration per an approved label, or once-weekly subcutaneous dosing used in trials, is reported only as it appears in the research and regulatory literature. This site does not publish personal dosing, does not tie doses to weight-loss outcomes, and none of this is medical advice. Dosing decisions belong with a licensed clinician.
The incretin class is the closest thing on this site to a compound group where women were genuinely studied, and it still leaves cycle-phase, menopause-specific, and, for the investigational agents, basic safety questions open. For the full female-evidence breakdown, including the contraceptive interaction and pregnancy status of each, see the semaglutide, tirzepatide, retatrutide, and cagrilintide profiles, which record how many of the underlying studies included women.